Back to Peptides
Fat LossMedium Risk

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus, GLP-1

Half-life:
~7 days (once-weekly dosing)

Administration Routes

subcutaneousoral
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is among the most prescribed and searched compounds in the weight loss space. Compounding pharmacies have produced semaglutide formulations under 503A and 503B frameworks, with significant provider interest across the telehealth and functional medicine space. Its mechanism involves both peripheral and central appetite suppression.

Primary Research Areas

  • fat_loss

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Providers Offering Semaglutide